Publications
- Targeted treatment with osimertinib in the adjuvant treatment of a patient with non‐small cell lung cancer – case report2023 | Third Faculty of Medicine
- Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?2022 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Two years longer and peaceful life thanks to alectinib2022 | Third Faculty of Medicine, Central Library of Charles University
- Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry2020 | Faculty of Medicine in Pilsen, Central Library of Charles University
- Role of alectinib in the treatment of advanced non-small cell lung cancer2020 | Third Faculty of Medicine
- EGFR mutations in non-small cell lung cancer - treatment options2019 | Third Faculty of Medicine
- Optimal procedure in treatments of advanced ALK-positive and ROS1-positive non-small cell lung cancers2019 | Third Faculty of Medicine
- Osimertinib and its use in the treatment of non-small cell lung carcinoma in the Czech Republic2018 | Third Faculty of Medicine
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
Loading network view...
